KRTX - Karuna Therapeutics: A Chance To Buy Into KarTX Promise At A Discount
Investment Thesis
Karuna Therapeutics (KRTX) was the most successful IPO in the US in 2019 in terms of percentage share price gain delivering a 420% overall gain after joining in July in an IPO priced at $16.
Karuna 1-year share price performance. Source: TradingView.
The catalyst for the gains was straightforward - the performance of Karuna's lead product candidate Karuna-xanomeline-trospium chloride ("KarXT") in a phase 2 trial of schizophrenia patients suffering from acute psychosis.
KarXT is a combination of 2 separate treatments. The first is xanomeline, a novel muscarinic agonist that the